IVERMECTIN

IVERMECTIN was reported 4537 times

IVERMECTIN is most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 MAZZOTTI REACTION 9 0.8182
1 VISCERAL LARVA MIGRANS 7 0.7778
2 NEMATODIASIS 9 0.2647
3 FILARIASIS 9 0.1765
4 HOOKWORM INFECTION 5 0.1471
5 EXPRESSIVE LANGUAGE DISORDER 35 0.1228
6 BIFIDOBACTERIUM INFECTION 3 0.1111
7 DISSEMINATED STRONGYLOIDIASIS 24 0.1096
8 LICE INFESTATION 23 0.1095
9 CONGENITAL MUSCLE ABSENCE 4 0.1026
10 SOMATIC DELUSION 21 0.0854
11 MALARIA 59 0.0837
12 STRONGYLOIDIASIS 125 0.0773
13 DRUG DEPENDENCE, ANTEPARTUM 4 0.0769
14 BLOOD SMEAR TEST ABNORMAL 6 0.0750
15 RHINOCEREBRAL MUCORMYCOSIS 26 0.0749
16 SCHISTOSOMIASIS 5 0.0649
17 CONJUNCTIVAL HAEMORRHAGE 237 0.0620
18 SCABIES 6 0.0351
19 ROSACEA 162 0.0347
20 ACARODERMATITIS 32 0.0293
21 INFESTATION 7 0.0270
22 TONGUE HAEMATOMA 5 0.0253
23 HELMINTHIC INFECTION 6 0.0247
24 INTRACRANIAL INFECTION 3 0.0240
25 BLADDER DISTENSION 3 0.0238
26 INFECTION PARASITIC 18 0.0230
27 NUCHAL RIGIDITY 18 0.0199
28 DELUSION OF PARASITOSIS 3 0.0191
29 THERAPEUTIC PRODUCT EFFECTIVE FOR UNAPPROVED INDICATION 7 0.0189
30 HERPES SIMPLEX HEPATITIS 4 0.0167
31 GLASGOW COMA SCALE ABNORMAL 4 0.0110
32 METHAEMOGLOBINAEMIA 25 0.0108
33 LOGORRHOEA 38 0.0108
34 SINUSITIS FUNGAL 8 0.0100
35 ANAL SPHINCTER ATONY 4 0.0093
36 HYPEREOSINOPHILIC SYNDROME 5 0.0092
37 MIXED LIVER INJURY 27 0.0090
38 INTENTION TREMOR 5 0.0088
39 GASTROINTESTINAL MICROORGANISM OVERGROWTH 3 0.0085
40 SELF-MEDICATION 34 0.0083
41 SUPRAPUBIC PAIN 4 0.0079
42 MACROCEPHALY 3 0.0077
43 LYMPHANGITIS 6 0.0075
44 FAECAL INCONTINENCE 33 0.0069
45 STUPOR 22 0.0068
46 PUSTULE 16 0.0067
47 SPIROMETRY ABNORMAL 4 0.0067
48 HEPATORENAL FAILURE 4 0.0066
49 NEUROPSYCHOLOGICAL SYMPTOMS 4 0.0066
50 LOCKED-IN SYNDROME 3 0.0065
51 PERIORAL DERMATITIS 4 0.0063
52 SYMMETRICAL DRUG-RELATED INTERTRIGINOUS AND FLEXURAL EXANTHEMA 5 0.0061
53 ENCEPHALOPATHY 147 0.0060
54 CHORIORETINOPATHY 8 0.0056
55 BRONCHIAL WALL THICKENING 4 0.0056
56 MONOPARESIS 10 0.0055
57 OCULAR HYPERAEMIA 258 0.0054
58 OSMOTIC DEMYELINATION SYNDROME 4 0.0054
59 SCROTAL SWELLING 5 0.0053
60 JOINT ANKYLOSIS 3 0.0053
61 COMA 247 0.0052
62 PRESCRIPTION DRUG USED WITHOUT A PRESCRIPTION 32 0.0052
63 GLOMERULONEPHRITIS MEMBRANOUS 6 0.0051
64 FUNGAEMIA 8 0.0051
65 SUPERINFECTION BACTERIAL 4 0.0050
66 VASCULAR PURPURA 7 0.0050
67 PARESIS 11 0.0049
68 MUTISM 7 0.0048
69 CONGENITAL CARDIOVASCULAR ANOMALY 4 0.0048
70 URINARY INCONTINENCE 136 0.0046
71 HEPATIC CYTOLYSIS 58 0.0045
72 CENTRAL NERVOUS SYSTEM INFECTION 5 0.0044
73 CONJUNCTIVAL HYPERAEMIA 15 0.0042
74 DIET REFUSAL 3 0.0041
75 PSEUDOMONAL SEPSIS 7 0.0040
76 GASTROINTESTINAL MOTILITY DISORDER 21 0.0039
77 TOXIC ENCEPHALOPATHY 19 0.0037
78 APPLICATION SITE INFLAMMATION 5 0.0036
79 VERTIGO 218 0.0036
80 ENDOCRINE OPHTHALMOPATHY 3 0.0035
81 PRURITUS ALLERGIC 4 0.0034
82 PARAPARESIS 6 0.0034
83 SUPERINFECTION 5 0.0033
84 PULSE ABNORMAL 8 0.0033
85 PNEUMONIA KLEBSIELLA 6 0.0033
86 ALPHA HAEMOLYTIC STREPTOCOCCAL INFECTION 3 0.0032
87 URINE ODOUR ABNORMAL 19 0.0032
88 INTRA-ABDOMINAL HAEMATOMA 4 0.0032
89 HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS 24 0.0032
90 ANOREXIA 41 0.0032
91 DANDRUFF 7 0.0032
92 DEPRESSED LEVEL OF CONSCIOUSNESS 123 0.0031
93 LICHENOID KERATOSIS 7 0.0031
94 HYPERSENSITIVITY VASCULITIS 8 0.0030
95 GASTRITIS EROSIVE 14 0.0030
96 DERMATITIS CONTACT 34 0.0030
97 ESCHERICHIA BACTERAEMIA 7 0.0030
98 APLASIA PURE RED CELL 10 0.0029
99 EOSINOPHILIA 50 0.0029
100 SKIN HYPOPIGMENTATION 5 0.0028
101 DECUBITUS ULCER 23 0.0028
102 ABNORMAL FAECES 23 0.0028
103 COMA SCALE ABNORMAL 8 0.0028
104 RASH PAPULAR 61 0.0027
105 PRODUCT PRESCRIBING ISSUE 58 0.0027
106 MARASMUS 4 0.0026
107 CORTISOL DECREASED 3 0.0026
108 DIFFICULTY IN WALKING 9 0.0026
109 ANTICOAGULATION DRUG LEVEL ABOVE THERAPEUTIC 4 0.0026
110 HYPERAMMONAEMIA 13 0.0026
111 SKIN DISCOMFORT 7 0.0026
112 FORMICATION 18 0.0026
113 NEUROTOXICITY 45 0.0026
114 ACUTE LUNG INJURY 3 0.0025
115 TOXIC EPIDERMAL NECROLYSIS 38 0.0025
116 EYELID OEDEMA 29 0.0025
117 HEPATOCELLULAR INJURY 35 0.0025
118 EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS 5 0.0024
119 BRONCHOPULMONARY ASPERGILLOSIS 19 0.0024
120 ACUTE GENERALISED EXANTHEMATOUS PUSTULOSIS 19 0.0024
121 CYTOLYTIC HEPATITIS 8 0.0024
122 CHEILITIS 13 0.0024
123 DERMATITIS ALLERGIC 30 0.0024
124 SYSTEMIC INFLAMMATORY RESPONSE SYNDROME 9 0.0024
125 MUCORMYCOSIS 6 0.0023
126 CERVICAL DYSPLASIA 5 0.0023
127 ENTEROCOCCAL INFECTION 11 0.0023
128 PRODUCT INEFFECTIVE FOR UNAPPROVED USE 6 0.0023
129 DRUG EFFECTIVE FOR UNAPPROVED INDICATION 66 0.0023
130 MULTIPLE ORGAN DYSFUNCTION SYNDROME 63 0.0022
131 ISCHAEMIC HEPATITIS 3 0.0022
132 MENINGITIS VIRAL 3 0.0022
133 PAIN OF SKIN 57 0.0021
134 MENINGITIS BACTERIAL 3 0.0021
135 URINARY HESITATION 5 0.0021
136 BLOOD IMMUNOGLOBULIN E INCREASED 5 0.0021
137 APPLICATION SITE DRYNESS 7 0.0021
138 UNDERWEIGHT 4 0.0020
139 DERMATITIS 42 0.0020
140 TACHYARRHYTHMIA 5 0.0020
141 HYPERPARATHYROIDISM SECONDARY 5 0.0020
142 LOCALISED OEDEMA 9 0.0019
143 DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS 50 0.0019
144 PRODUCT USE IN UNAPPROVED INDICATION 481 0.0019
145 ABNORMAL BEHAVIOUR 76 0.0019
146 LIVEDO RETICULARIS 4 0.0019
147 SKIN TIGHTNESS 9 0.0019
148 MEGACOLON 3 0.0019
149 TEMPOROMANDIBULAR JOINT SYNDROME 5 0.0019
150 SKIN IRRITATION 85 0.0019
151 PEMPHIGOID 14 0.0019
152 BACTERIAL SEPSIS 6 0.0018
153 CEREBELLAR SYNDROME 4 0.0018
154 RED BLOOD CELL COUNT INCREASED 5 0.0018
155 APPLICATION SITE SWELLING 9 0.0018
156 LYME DISEASE 6 0.0018
157 DERMATITIS BULLOUS 13 0.0018
158 RASH PUSTULAR 13 0.0018
159 MULTIPLE USE OF SINGLE-USE PRODUCT 10 0.0018
160 KLEBSIELLA INFECTION 9 0.0018
161 INTENTIONAL UNDERDOSE 13 0.0018
162 EROSIVE OESOPHAGITIS 3 0.0018
163 APHASIA 53 0.0018
164 MYCOBACTERIAL INFECTION 3 0.0017
165 DRUG INEFFECTIVE FOR UNAPPROVED INDICATION 95 0.0017
166 HYPERREFLEXIA 6 0.0017
167 SHOCK HAEMORRHAGIC 14 0.0017
168 SKIN BURNING SENSATION 123 0.0017
169 CREPITATIONS 5 0.0017
170 REBOUND ACID HYPERSECRETION 5 0.0017
171 VENTRICULAR ARRHYTHMIA 6 0.0016
172 ESSENTIAL HYPERTENSION 3 0.0016
173 SEBORRHOEA 6 0.0016
174 BODY TEMPERATURE ABNORMAL 3 0.0016
175 PRODUCT PHYSICAL CONSISTENCY ISSUE 9 0.0016
176 DERMATITIS EXFOLIATIVE 8 0.0016
177 ESCHERICHIA INFECTION 13 0.0016
178 ASTHENIA 592 0.0016
179 EOSINOPHIL COUNT INCREASED 13 0.0016
180 SKIN WARM 9 0.0015
181 RASH MACULO-PAPULAR 34 0.0015
182 ALTERED STATE OF CONSCIOUSNESS 33 0.0015
183 LUNG OPACITY 4 0.0015
184 POLYARTHRITIS 8 0.0015
185 DIPLEGIA 3 0.0015
186 ORAL DISCOMFORT 21 0.0015
187 SCAB 17 0.0015
188 STEVENS-JOHNSON SYNDROME 33 0.0015
189 APPLICATION SITE EXFOLIATION 6 0.0015
190 COVID-19 PNEUMONIA 17 0.0014
191 MUSCLE FATIGUE 6 0.0014
192 ACUTE RESPIRATORY DISTRESS SYNDROME 25 0.0014
193 PYREXIA 486 0.0014
194 SKIN HYPERPIGMENTATION 12 0.0014
195 INCOHERENT 9 0.0014
196 PERIPHERAL COLDNESS 19 0.0014
197 SKIN SWELLING 12 0.0014
198 HENOCH-SCHONLEIN PURPURA 3 0.0014
199 ONYCHOMYCOSIS 6 0.0014
200 CYTOMEGALOVIRUS INFECTION REACTIVATION 6 0.0014
201 FAECES PALE 3 0.0013
202 MENINGITIS 9 0.0013
203 MUSCULOSKELETAL DISCOMFORT 23 0.0013
204 SEPTIC SHOCK 57 0.0013
205 DUODENITIS 4 0.0013
206 ENCEPHALITIS 9 0.0013
207 ORAL INFECTION 5 0.0013
208 TESTICULAR PAIN 4 0.0013
209 PRODUCT ODOUR ABNORMAL 13 0.0012
210 LYMPHADENITIS 3 0.0012
211 INCONTINENCE 13 0.0012
212 APPLICATION SITE BURN 6 0.0012
213 ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY POSITIVE VASCULITIS 3 0.0012
214 DRUG ADMINISTRATION ERROR 37 0.0012
215 IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME 6 0.0012
216 DYSSTASIA 35 0.0012
217 MENTAL STATUS CHANGES 33 0.0012
218 DISORIENTATION 47 0.0012
219 NERVOUS SYSTEM DISORDER 37 0.0012
220 CANDIDA INFECTION 20 0.0012
221 CHEMICAL BURN OF SKIN 3 0.0012
222 CANCER PAIN 3 0.0012
223 ELECTROCARDIOGRAM QRS COMPLEX PROLONGED 6 0.0012
224 DISSEMINATED TUBERCULOSIS 3 0.0012
225 ERYTHEMA 239 0.0012
226 HEPATITIS TOXIC 3 0.0012
227 ACUTE RESPIRATORY FAILURE 22 0.0011
228 BRONCHIOLITIS 4 0.0011
229 PAPULE 8 0.0011
230 NYSTAGMUS 6 0.0011
231 FIBRIN D DIMER INCREASED 4 0.0011
232 SKIN WEEPING 4 0.0011
233 CHROMATURIA 25 0.0011
234 PHOTOPSIA 7 0.0011
235 BLOOD PRESSURE ABNORMAL 22 0.0011
236 GASTRIC PERFORATION 3 0.0011
237 ATAXIA 13 0.0011
238 HAIR DISORDER 9 0.0011
239 FOOD INTOLERANCE 4 0.0011
240 PARADOXICAL DRUG REACTION 4 0.0011
241 VIRAL MUTATION IDENTIFIED 4 0.0011
242 HERPES SIMPLEX 7 0.0011
243 AGRANULOCYTOSIS 20 0.0011
244 HEART RATE ABNORMAL 6 0.0011
245 DIABETIC COMA 3 0.0011
246 HEPATIC NECROSIS 4 0.0011
247 PERIORBITAL SWELLING 6 0.0011
248 PARANASAL SINUS DISCOMFORT 4 0.0011
249 PETECHIAE 11 0.0011
250 GENERALISED OEDEMA 13 0.0010
251 ILEUS 13 0.0010
252 HEADACHE 653 0.0010
253 HYPERTONIC BLADDER 3 0.0010
254 PRURITUS 393 0.0010
255 AGITATION 75 0.0010
256 PURPURA 9 0.0010
257 HEPATITIS FULMINANT 3 0.0010
258 FACE OEDEMA 17 0.0010
259 AUTOIMMUNE HEPATITIS 7 0.0010
260 METABOLIC ENCEPHALOPATHY 3 0.0010
261 BACK PAIN 232 0.0010
262 ACNE CYSTIC 3 0.0010
263 HIV INFECTION 3 0.0010
264 SKIN REACTION 14 0.0010
265 DUODENAL ULCER 7 0.0010
266 VITAMIN B12 DEFICIENCY 4 0.0010
267 KERATITIS 3 0.0010
268 OLIGURIA 6 0.0010
269 THYROID FUNCTION TEST ABNORMAL 4 0.0010
270 SECRETION DISCHARGE 12 0.0010
271 APLASTIC ANAEMIA 5 0.0010
272 PULSELESS ELECTRICAL ACTIVITY 4 0.0010
273 APPLICATION SITE ERYTHEMA 25 0.0010
274 APPLICATION SITE PAIN 21 0.0010
275 POISONING DELIBERATE 9 0.0009
276 CEREBRAL DISORDER 7 0.0009
277 VASCULITIS 11 0.0009
278 HEPATIC PAIN 4 0.0009
279 SWELLING FACE 61 0.0009
280 ABNORMAL SENSATION IN EYE 4 0.0009
281 VIROLOGIC FAILURE 5 0.0009
282 MULTI-ORGAN FAILURE 16 0.0009
283 HORDEOLUM 4 0.0009
284 ERYTHEMA OF EYELID 5 0.0009
285 DISSEMINATED INTRAVASCULAR COAGULATION 13 0.0009
286 HYPERTHERMIA 7 0.0009
287 CONJUNCTIVITIS 17 0.0009
288 ACIDOSIS 7 0.0009
289 HEPATOMEGALY 9 0.0009
290 SKIN EXFOLIATION 77 0.0009
291 INFUSION SITE HAEMORRHAGE 3 0.0009
292 IMPAIRED QUALITY OF LIFE 13 0.0009
293 SKIN DISORDER 30 0.0009
294 SKIN MASS 6 0.0009
295 TORSADE DE POINTES 7 0.0009
296 PULMONARY ALVEOLAR HAEMORRHAGE 5 0.0009
297 INTENTIONAL PRODUCT MISUSE 78 0.0009
298 OCULAR DISCOMFORT 10 0.0009
299 INCORRECT DRUG ADMINISTRATION DURATION 25 0.0009
300 CHOLESTASIS 17 0.0009
301 CHILLS 103 0.0009
302 GAIT DISTURBANCE 168 0.0009
303 RED BLOOD CELL COUNT DECREASED 25 0.0009
304 HYPERBILIRUBINAEMIA 9 0.0009
305 NEPHROGENIC ANAEMIA 4 0.0009
306 HYPERVENTILATION 5 0.0009
307 RALES 5 0.0009
308 NECK PAIN 48 0.0009
309 SPEECH DISORDER 45 0.0009
310 RASH ERYTHEMATOUS 41 0.0009
311 NECROTISING FASCIITIS 3 0.0009
312 RESPIRATORY FAILURE 62 0.0008
313 CLOSTRIDIUM DIFFICILE COLITIS 9 0.0008
314 BACTERAEMIA 10 0.0008
315 EXPIRED PRODUCT ADMINISTERED 28 0.0008
316 HEMIPLEGIA 7 0.0008
317 SQUAMOUS CELL CARCINOMA OF SKIN 5 0.0008
318 ORAL DISORDER 6 0.0008
319 LIP SWELLING 27 0.0008
320 ARTHROPOD BITE 6 0.0008
321 TACHYPNOEA 11 0.0008
322 INFLAMMATORY MARKER INCREASED 4 0.0008
323 MALNUTRITION 9 0.0008
324 INFUSION SITE EXTRAVASATION 5 0.0008
325 RASH MACULAR 28 0.0008
326 AUTOIMMUNE THYROIDITIS 3 0.0008
327 EAR INFECTION 21 0.0008
328 PRURITUS GENERALISED 17 0.0008
329 HEPATITIS 20 0.0008
330 LOSS OF CONSCIOUSNESS 100 0.0008
331 GINGIVAL DISORDER 3 0.0008
332 MYALGIA 132 0.0008
333 ELECTROLYTE IMBALANCE 9 0.0008
334 HEPATITIS ACUTE 5 0.0008
335 ABASIA 19 0.0008
336 SWOLLEN TONGUE 24 0.0008
337 EPIGASTRIC DISCOMFORT 3 0.0008
338 PARTIAL SEIZURES 4 0.0008
339 HEPATIC FAILURE 23 0.0008
340 SCRATCH 8 0.0008
341 APATHY 11 0.0008
342 ERYTHEMA MULTIFORME 7 0.0007
343 BLOOD DISORDER 6 0.0007
344 PRODUCT AVAILABILITY ISSUE 17 0.0007
345 ENURESIS 3 0.0007
346 APPLICATION SITE DISCOLOURATION 3 0.0007
347 HYDROCEPHALUS 4 0.0007
348 DRUG ERUPTION 13 0.0007
349 HICCUPS 6 0.0007
350 SKIN LESION 20 0.0007
351 APPLICATION SITE IRRITATION 9 0.0007
352 CYTOMEGALOVIRUS INFECTION 12 0.0007
353 RASH PRURITIC 39 0.0007
354 URINARY RETENTION 24 0.0007
355 DRY SKIN 96 0.0007
356 INTENTIONAL PRODUCT USE ISSUE 63 0.0007
357 INAPPROPRIATE SCHEDULE OF DRUG ADMINISTRATION 51 0.0007
358 ASCITES 21 0.0007
359 VITREOUS FLOATERS 7 0.0007
360 ESCHERICHIA URINARY TRACT INFECTION 3 0.0007
361 INCORRECT DRUG ADMINISTRATION RATE 3 0.0007
362 ABSCESS LIMB 3 0.0007
363 GENERALISED ERYTHEMA 4 0.0007
364 PSEUDOMONAS INFECTION 6 0.0007
365 ANURIA 6 0.0007
366 ADVERSE EVENT 64 0.0007
367 CARDIAC MURMUR 6 0.0007
368 THERAPY NON-RESPONDER 31 0.0007
369 ORTHOSTATIC HYPOTENSION 12 0.0007
370 DRY THROAT 7 0.0007
371 IMMUNE SYSTEM DISORDER 9 0.0007
372 FEELING COLD 19 0.0007
373 LUNG INFILTRATION 6 0.0007
374 SENSITIVE SKIN 5 0.0007
375 HYPOPHOSPHATAEMIA 5 0.0007
376 SKIN HAEMORRHAGE 10 0.0007
377 EYE DISCHARGE 7 0.0007
378 FEELING DRUNK 5 0.0007
379 FACIAL PAIN 6 0.0007
380 THERAPEUTIC RESPONSE UNEXPECTED 30 0.0007
381 IRON DEFICIENCY 3 0.0007
382 HEPATITIS CHOLESTATIC 4 0.0007
383 PSYCHOMOTOR HYPERACTIVITY 11 0.0007
384 SUDDEN DEATH 7 0.0007
385 APPLICATION SITE PRURITUS 15 0.0007
386 OSTEOPENIA 10 0.0007
387 DERMATITIS ACNEIFORM 4 0.0007
388 UROSEPSIS 6 0.0006
389 SMALL INTESTINAL OBSTRUCTION 8 0.0006
390 FOOD ALLERGY 5 0.0006
391 SLEEP DISORDER DUE TO A GENERAL MEDICAL CONDITION 11 0.0006
392 MUSCULOSKELETAL CHEST PAIN 10 0.0006
393 SCOLIOSIS 4 0.0006
394 BLOOD ALKALINE PHOSPHATASE INCREASED 16 0.0006
395 HYPOTENSION 129 0.0006
396 DIARRHOEA HAEMORRHAGIC 6 0.0006
397 PRE-EXISTING CONDITION IMPROVED 4 0.0006
398 SWELLING OF EYELID 4 0.0006
399 PRODUCT ADMINISTRATION INTERRUPTED 5 0.0006
400 COVID-19 110 0.0006
401 ATRIAL FLUTTER 5 0.0006
402 HYPOVOLAEMIC SHOCK 3 0.0006
403 BLISTER 35 0.0006
404 DRUG INEFFECTIVE 819 0.0006
405 HEAD DISCOMFORT 11 0.0006
406 ATELECTASIS 6 0.0006
407 EYE SWELLING 23 0.0006
408 HORMONE LEVEL ABNORMAL 3 0.0006
409 PHARYNGEAL SWELLING 6 0.0006
410 EATING DISORDER 13 0.0006
411 ASPERGILLUS INFECTION 4 0.0006
412 DERMATITIS ATOPIC 32 0.0006
413 ALANINE AMINOTRANSFERASE INCREASED 37 0.0006
414 EYE PAIN 34 0.0006
415 DRUG LEVEL DECREASED 6 0.0006
416 TOOTH ABSCESS 6 0.0006
417 LIVER DISORDER 26 0.0006
418 DRUG INTERACTION 93 0.0006
419 ACUTE HEPATIC FAILURE 8 0.0006
420 PHOTOPHOBIA 11 0.0006
421 OFF LABEL USE 512 0.0006
422 APPLICATION SITE RASH 8 0.0006
423 TEMPERATURE INTOLERANCE 6 0.0006
424 ONYCHOCLASIS 4 0.0006
425 BENIGN PROSTATIC HYPERPLASIA 3 0.0006
426 FOETAL DEATH 3 0.0006
427 DELIRIUM 20 0.0006
428 LARGE INTESTINE PERFORATION 4 0.0006
429 EXTRASYSTOLES 4 0.0006
430 NAIL DISORDER 5 0.0006
431 APPLICATION SITE REACTION 4 0.0006
432 PRESCRIBED OVERDOSE 11 0.0006
433 HYPERCALCAEMIA 7 0.0006
434 SEASONAL ALLERGY 8 0.0006
435 ASPARTATE AMINOTRANSFERASE INCREASED 30 0.0006
436 CONFUSIONAL STATE 91 0.0006
437 HEREDITARY ANGIOEDEMA 6 0.0006
438 PARALYSIS 8 0.0006
439 POISONING 7 0.0006
440 ECZEMA 29 0.0006
441 OROPHARYNGEAL DISCOMFORT 5 0.0006
442 SKIN LACERATION 6 0.0006
443 PATHOGEN RESISTANCE 5 0.0005
444 LIQUID PRODUCT PHYSICAL ISSUE 4 0.0005
445 HEART RATE INCREASED 54 0.0005
446 PHOTOSENSITIVITY REACTION 9 0.0005
447 PNEUMONIA BACTERIAL 5 0.0005
448 RESPIRATORY DISTRESS 15 0.0005
449 INFUSION SITE PAIN 7 0.0005
450 BLINDNESS TRANSIENT 4 0.0005
451 ACNE 41 0.0005
452 INTRACRANIAL PRESSURE INCREASED 3 0.0005
453 ACUTE PULMONARY OEDEMA 3 0.0005
454 ANHEDONIA 14 0.0005
455 SARS-COV-2 TEST POSITIVE 7 0.0005
456 SCAR 9 0.0005
457 HAEMODYNAMIC INSTABILITY 4 0.0005
458 HYPERTONIA 3 0.0005
459 INSURANCE ISSUE 8 0.0005
460 SKIN DISCOLOURATION 24 0.0005
461 JOINT RANGE OF MOTION DECREASED 7 0.0005
462 HERPES VIRUS INFECTION 3 0.0005
463 SEPSIS 58 0.0005
464 DRY MOUTH 42 0.0005
465 HOT FLUSH 39 0.0005
466 ARTHRALGIA 214 0.0005
467 HYPOXIA 18 0.0005
468 BRAIN FOG 8 0.0005
469 DRUG-INDUCED LIVER INJURY 16 0.0005
470 VISION BLURRED 70 0.0005
471 ENERGY INCREASED 3 0.0005
472 TREATMENT FAILURE 42 0.0005
473 IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME 3 0.0005
474 ACUTE KIDNEY INJURY 77 0.0005
475 MYOCLONUS 6 0.0005
476 RESPIRATORY DISORDER 15 0.0005
477 PRODUCT USE ISSUE 94 0.0005
478 GANGRENE 3 0.0005
479 SENSORY LOSS 4 0.0005
480 CONDITION AGGRAVATED 151 0.0005
481 RHINITIS 4 0.0005
482 LYMPHOPENIA 7 0.0005
483 SLUGGISHNESS 5 0.0005
484 BODY TEMPERATURE INCREASED 10 0.0005
485 LUNG DISORDER 24 0.0005
486 INAPPROPRIATE ANTIDIURETIC HORMONE SECRETION 5 0.0005
487 LARYNGEAL OEDEMA 3 0.0005
488 UPPER-AIRWAY COUGH SYNDROME 4 0.0005
489 INFLAMMATION 25 0.0005
490 CYST 6 0.0005
491 JAUNDICE 13 0.0005
492 PNEUMONIA ASPIRATION 12 0.0005
493 COAGULOPATHY 8 0.0005
494 WEIGHT FLUCTUATION 5 0.0005
495 RASH 208 0.0005
496 EYE PRURITUS 16 0.0005
497 ABDOMINAL PAIN LOWER 12 0.0005
498 POOR QUALITY PRODUCT ADMINISTERED 5 0.0005
499 CHRONIC KIDNEY DISEASE 36 0.0005
500 FOREIGN BODY SENSATION IN EYES 3 0.0005
501 CIRCULATORY COLLAPSE 8 0.0005
502 FACIAL PARALYSIS 4 0.0005
503 EYE IRRITATION 27 0.0005
504 ENTERITIS 3 0.0005
505 VITAMIN D DECREASED 4 0.0005
506 OEDEMA PERIPHERAL 57 0.0005
507 DRUG RESISTANCE 12 0.0005
508 INCORRECT ROUTE OF PRODUCT ADMINISTRATION 8 0.0005
509 UNRESPONSIVE TO STIMULI 12 0.0005
510 LACRIMATION INCREASED 14 0.0005
511 ECONOMIC PROBLEM 7 0.0005
512 PRODUCT PRESCRIBING ERROR 11 0.0005
513 DIARRHOEA 295 0.0005
514 HYPOGAMMAGLOBULINAEMIA 3 0.0005
515 INTENTIONAL DOSE OMISSION 13 0.0005
516 HEPATIC FUNCTION ABNORMAL 17 0.0005
517 PHARYNGEAL OEDEMA 7 0.0005
518 CARDIO-RESPIRATORY ARREST 19 0.0005
519 LABELLED DRUG-DRUG INTERACTION MEDICATION ERROR 4 0.0005
520 RENAL FAILURE 60 0.0005
521 FUNGAL INFECTION 15 0.0004
522 HEPATOTOXICITY 10 0.0004
523 THROMBOCYTOPENIA 50 0.0004
524 WHITE BLOOD CELL COUNT DECREASED 48 0.0004
525 REBOUND EFFECT 5 0.0004
526 GENERAL PHYSICAL CONDITION ABNORMAL 3 0.0004
527 BLINDNESS 18 0.0004
528 SHOCK 10 0.0004
529 VOMITING 204 0.0004
530 LARGE INTESTINE POLYP 3 0.0004
531 INTERVERTEBRAL DISC DEGENERATION 4 0.0004
532 PRODUCT DISTRIBUTION ISSUE 4 0.0004
533 HUNGER 6 0.0004
534 APHONIA 6 0.0004
535 ABORTION INDUCED 4 0.0004
536 FEELING HOT 26 0.0004
537 DIPLOPIA 11 0.0004
538 HAND FRACTURE 3 0.0004
539 COLITIS 16 0.0004
540 GAIT INABILITY 14 0.0004
541 ELECTROCARDIOGRAM QT PROLONGED 15 0.0004
542 SEIZURE 48 0.0004
543 FAECES DISCOLOURED 9 0.0004
544 NO ADVERSE EVENT 75 0.0004
545 BURNING SENSATION 29 0.0004
546 FLUSHING 42 0.0004
547 ABDOMINAL PAIN 96 0.0004
548 GASTROENTERITIS 6 0.0004
549 VITAMIN D DEFICIENCY 4 0.0004
550 ORAL HERPES 8 0.0004
551 MELAENA 9 0.0004
552 CYTOPENIA 5 0.0004
553 BLOOD BILIRUBIN INCREASED 11 0.0004
554 METABOLIC ACIDOSIS 13 0.0004
555 BODY TEMPERATURE DECREASED 4 0.0004
556 DISABILITY 8 0.0004
557 LIGAMENT SPRAIN 4 0.0004
558 GENERAL SYMPTOM 3 0.0004
559 SALIVARY HYPERSECRETION 4 0.0004
560 BRAIN INJURY 4 0.0004
561 CYTOKINE RELEASE SYNDROME 8 0.0004
562 PRODUCTIVE COUGH 19 0.0004
563 TOXICITY TO VARIOUS AGENTS 67 0.0004
564 TOXIC SKIN ERUPTION 4 0.0004
565 LYMPHADENOPATHY 14 0.0004
566 PANCYTOPENIA 22 0.0004
567 EYELID PTOSIS 4 0.0004
568 INTENTIONAL OVERDOSE 25 0.0004
569 MYDRIASIS 5 0.0004
570 PRODUCT DOSE OMISSION IN ERROR 11 0.0004
571 MUSCULOSKELETAL STIFFNESS 34 0.0004
572 SKIN ULCER 10 0.0004
573 LEUKOCYTOSIS 7 0.0004
574 HIATUS HERNIA 5 0.0004
575 VENTRICULAR EXTRASYSTOLES 4 0.0004
576 THERAPY PARTIAL RESPONDER 6 0.0004
577 END STAGE RENAL DISEASE 7 0.0004
578 NODULE 5 0.0004
579 ACCIDENTAL OVERDOSE 14 0.0004
580 MULTIPLE ALLERGIES 3 0.0004
581 FOLLICULITIS 4 0.0004
582 PARAESTHESIA 60 0.0004
583 JOINT STIFFNESS 10 0.0004
584 GASTRITIS 10 0.0004
585 TOOTH INFECTION 5 0.0004
586 PULMONARY CONGESTION 5 0.0004
587 ADVERSE REACTION 5 0.0004
588 CELLULITIS 19 0.0004
589 DYSPHONIA 22 0.0004
590 BACTERIAL INFECTION 7 0.0004
591 LIVER FUNCTION TEST INCREASED 8 0.0004
592 DECREASED ACTIVITY 4 0.0004
593 PSORIATIC ARTHROPATHY 15 0.0004
594 ILLNESS 38 0.0004
595 OEDEMA 20 0.0004
596 MENTAL DISORDER 16 0.0004
597 ASPHYXIA 3 0.0004
598 PNEUMONITIS 10 0.0004
599 ALOPECIA 72 0.0004
600 INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION 66 0.0004
601 OESOPHAGITIS 4 0.0004
602 WHITE BLOOD CELL COUNT INCREASED 14 0.0004
603 STAPHYLOCOCCAL INFECTION 12 0.0004
604 ERUCTATION 7 0.0004
605 DRY EYE 18 0.0004
606 VENTRICULAR FIBRILLATION 4 0.0004
607 TRANSAMINASES INCREASED 8 0.0004
608 BALANCE DISORDER 31 0.0004
609 SKIN FISSURES 7 0.0004
610 URTICARIA 60 0.0004
611 DISEASE RECURRENCE 17 0.0004
612 OVERDOSE 77 0.0004
613 EYE INFECTION 4 0.0004
614 BRONCHOSPASM 5 0.0004
615 MYOCARDITIS 4 0.0003
616 HYPERSOMNIA 10 0.0003
617 CARDIAC FAILURE 28 0.0003
618 SOMNOLENCE 70 0.0003
619 BLOOD MAGNESIUM DECREASED 3 0.0003
620 MUSCLE TWITCHING 8 0.0003
621 DYSARTHRIA 13 0.0003
622 FEEDING DISORDER 7 0.0003
623 DEHYDRATION 46 0.0003
624 SPINAL PAIN 4 0.0003
625 IMMUNOSUPPRESSION 3 0.0003
626 URINARY TRACT INFECTION 58 0.0003
627 LACTIC ACIDOSIS 11 0.0003
628 BRADYCARDIA 18 0.0003
629 MUSCLE RIGIDITY 4 0.0003
630 ANAL INCONTINENCE 3 0.0003
631 MOUTH ULCERATION 7 0.0003
632 HALLUCINATION, VISUAL 7 0.0003
633 PALLOR 9 0.0003
634 HYPOGLYCAEMIA 16 0.0003
635 BURSITIS 4 0.0003
636 PRESYNCOPE 8 0.0003
637 HYPERSENSITIVITY 61 0.0003
638 EXOSTOSIS 3 0.0003
639 INCREASED TENDENCY TO BRUISE 3 0.0003
640 GLOMERULAR FILTRATION RATE DECREASED 4 0.0003
641 NERVE COMPRESSION 3 0.0003
642 UPPER RESPIRATORY TRACT INFECTION 15 0.0003
643 BREAST CANCER STAGE I 3 0.0003
644 INCORRECT PRODUCT ADMINISTRATION DURATION 7 0.0003
645 HAEMOPTYSIS 9 0.0003
646 PHARYNGITIS 4 0.0003
647 HEPATIC STEATOSIS 6 0.0003
648 HEPATIC ENCEPHALOPATHY 3 0.0003
649 BASAL CELL CARCINOMA 5 0.0003
650 ARTERIOSCLEROSIS 3 0.0003
651 PAIN IN JAW 9 0.0003
652 BRAIN OEDEMA 4 0.0003
653 FOOT FRACTURE 6 0.0003
654 OSTEOPOROSIS 13 0.0003
655 MUSCLE ATROPHY 4 0.0003
656 BLOOD LACTATE DEHYDROGENASE INCREASED 5 0.0003
657 TACHYCARDIA 28 0.0003
658 RESPIRATORY TRACT CONGESTION 5 0.0003
659 EYE INFLAMMATION 3 0.0003
660 ULCER 5 0.0003
661 WEIGHT DECREASED 87 0.0003
662 DISCOMFORT 19 0.0003
663 ANAPHYLACTIC SHOCK 8 0.0003
664 RHINORRHOEA 20 0.0003
665 DECREASED IMMUNE RESPONSIVENESS 3 0.0003
666 METASTASES TO BONE 5 0.0003
667 BEDRIDDEN 4 0.0003
668 EYE DISORDER 10 0.0003
669 ORAL CANDIDIASIS 4 0.0003
670 OXYGEN SATURATION DECREASED 17 0.0003
671 THERAPEUTIC RESPONSE SHORTENED 10 0.0003
672 IRRITABILITY 18 0.0003
673 PRODUCT ADMINISTRATION ERROR 6 0.0003
674 HYPOTHERMIA 3 0.0003
675 CIRCUMSTANCE OR INFORMATION CAPABLE OF LEADING TO MEDICATION ERROR 10 0.0003
676 THROAT TIGHTNESS 8 0.0003
677 TREMOR 49 0.0003
678 ANGIOEDEMA 13 0.0003
679 GINGIVAL BLEEDING 4 0.0003
680 HAEMATURIA 10 0.0003
681 BLOOD CREATININE INCREASED 19 0.0003
682 ABDOMINAL PAIN UPPER 59 0.0003
683 CEREBRAL INFARCTION 7 0.0003
684 BLOOD PRESSURE DECREASED 19 0.0003
685 HYPERKALAEMIA 10 0.0003
686 DYSPHAGIA 27 0.0003
687 RENAL FAILURE ACUTE 12 0.0003
688 BODY HEIGHT DECREASED 3 0.0003
689 THERAPEUTIC RESPONSE DECREASED 17 0.0003
690 COUGH 78 0.0003
691 INFLUENZA 31 0.0003
692 PARAESTHESIA ORAL 4 0.0003
693 GASTROENTERITIS VIRAL 5 0.0003
694 WRONG TECHNIQUE IN PRODUCT USAGE PROCESS 56 0.0003
695 ANOSMIA 4 0.0003
696 HAEMATEMESIS 7 0.0003
697 VISUAL IMPAIRMENT 34 0.0003
698 EXPOSURE DURING PREGNANCY 17 0.0003
699 PAIN 168 0.0003
700 SINUSITIS 28 0.0003
701 GASTROINTESTINAL PAIN 3 0.0003
702 ERECTILE DYSFUNCTION 7 0.0003
703 NEUTROPENIA 37 0.0003
704 PLATELET COUNT DECREASED 29 0.0003
705 VISUAL ACUITY REDUCED 9 0.0003
706 LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES 13 0.0003
707 OROPHARYNGEAL PAIN 25 0.0003
708 PULMONARY MASS 4 0.0003
709 COLON CANCER 4 0.0003
710 THINKING ABNORMAL 5 0.0003
711 IMMUNODEFICIENCY 4 0.0003
712 MUCOSAL INFLAMMATION 7 0.0003
713 NEPHROPATHY TOXIC 3 0.0003
714 PANCREATITIS ACUTE 6 0.0003
715 HYPOCALCAEMIA 5 0.0003
716 IMPAIRED DRIVING ABILITY 3 0.0003
717 SLEEP APNOEA SYNDROME 5 0.0003
718 AMNESIA 17 0.0003
719 TINNITUS 12 0.0003
720 POST PROCEDURAL COMPLICATION 5 0.0003
721 DRUG PRESCRIBING ERROR 5 0.0003
722 PNEUMONIA 84 0.0003
723 ABDOMINAL DISTENSION 27 0.0003
724 TENDONITIS 4 0.0003
725 GASTROINTESTINAL DISORDER 23 0.0003
726 MOOD ALTERED 7 0.0003
727 SURGERY 15 0.0003
728 MUSCULAR WEAKNESS 29 0.0003
729 SLEEP DISORDER 18 0.0003
730 RESPIRATORY ARREST 7 0.0003
731 ARRHYTHMIA 12 0.0003
732 ANAPHYLACTIC REACTION 14 0.0003
733 GASTROINTESTINAL HAEMORRHAGE 21 0.0003
734 CYSTITIS 8 0.0003
735 PREMATURE DELIVERY 4 0.0003
736 OBESITY 4 0.0003
737 RENAL IMPAIRMENT 21 0.0002
738 HEPATIC ENZYME INCREASED 17 0.0002
739 SENSORY DISTURBANCE 4 0.0002
740 ASTHMA 28 0.0002
741 PALPITATIONS 29 0.0002
742 ADRENAL INSUFFICIENCY 3 0.0002
743 HYPERGLYCAEMIA 9 0.0002
744 MUSCLE TIGHTNESS 4 0.0002
745 TASTE DISORDER 5 0.0002
746 ANAEMIA 47 0.0002
747 CHEST PAIN 45 0.0002
748 CARDIAC ARREST 20 0.0002
749 DYSPNOEA 137 0.0002
750 DECREASED APPETITE 56 0.0002
751 INSOMNIA 64 0.0002
752 SYNCOPE 24 0.0002
753 DIZZINESS 119 0.0002
754 DRUG INTOLERANCE 23 0.0002
755 PRODUCT QUALITY ISSUE 32 0.0002
756 HAEMATOCHEZIA 13 0.0002
757 BLOOD PRESSURE INCREASED 36 0.0002
758 HYPOPHAGIA 6 0.0002
759 FATIGUE 182 0.0002
760 SKIN CANCER 5 0.0002
761 RASH GENERALISED 6 0.0002
762 RESPIRATORY TRACT INFECTION 6 0.0002
763 LOCAL SWELLING 4 0.0002
764 FLATULENCE 13 0.0002
765 INFECTION 33 0.0002
766 PERIPHERAL SWELLING 35 0.0002
767 HERPES ZOSTER 13 0.0002
768 LETHARGY 13 0.0002
769 HALLUCINATION 17 0.0002
770 THERAPEUTIC PRODUCT EFFECT INCOMPLETE 16 0.0002
771 TOOTH DISORDER 5 0.0002
772 GENERAL PHYSICAL HEALTH DETERIORATION 26 0.0002
773 MATERNAL EXPOSURE DURING PREGNANCY 20 0.0002
774 HAIR TEXTURE ABNORMAL 3 0.0002
775 THIRST 4 0.0002
776 INCORRECT ROUTE OF DRUG ADMINISTRATION 8 0.0002
777 MUSCLE SPASMS 41 0.0002
778 ORAL PAIN 5 0.0002
779 THROAT IRRITATION 10 0.0002
780 EXTRA DOSE ADMINISTERED 9 0.0002
781 MYELOSUPPRESSION 8 0.0002
782 FREQUENT BOWEL MOVEMENTS 6 0.0002
783 PSORIASIS 29 0.0002
784 TOOTHACHE 4 0.0002
785 LIMB INJURY 6 0.0002
786 HYPOAESTHESIA 33 0.0002
787 CRYING 8 0.0002
788 IMPAIRED GASTRIC EMPTYING 3 0.0002
789 C-REACTIVE PROTEIN INCREASED 8 0.0002
790 BONE DISORDER 4 0.0002
791 CENTRAL NERVOUS SYSTEM LESION 3 0.0002
792 PRODUCT ADMINISTERED AT INAPPROPRIATE SITE 4 0.0002
793 NEPHROLITHIASIS 10 0.0002
794 PRODUCT DOSE OMISSION ISSUE 64 0.0002
795 NIGHT SWEATS 7 0.0002
796 DIVERTICULITIS 6 0.0002
797 ARTHRITIS 17 0.0002
798 MASS 3 0.0002
799 CARPAL TUNNEL SYNDROME 3 0.0002
800 BLOOD TEST ABNORMAL 3 0.0002
801 BLINDNESS UNILATERAL 3 0.0002
802 DYSPNOEA EXERTIONAL 8 0.0002
803 NAUSEA 168 0.0002
804 INTESTINAL OBSTRUCTION 8 0.0002
805 BLOOD SODIUM DECREASED 4 0.0002
806 MUSCULOSKELETAL DISORDER 4 0.0002
807 CONVULSION 12 0.0002
808 INCREASED APPETITE 4 0.0002
809 CARDIOGENIC SHOCK 3 0.0002
810 BLOOD CREATINE PHOSPHOKINASE INCREASED 6 0.0002
811 LOCALISED INFECTION 5 0.0002
812 COMPLICATION ASSOCIATED WITH DEVICE 3 0.0002
813 EMOTIONAL DISTRESS 25 0.0002
814 LIVER FUNCTION TEST ABNORMAL 6 0.0002
815 DRUG EXPOSURE DURING PREGNANCY 7 0.0002
816 UNDERDOSE 15 0.0002
817 CHOKING 4 0.0002
818 BONE PAIN 12 0.0002
819 KIDNEY INFECTION 4 0.0002
820 DRUG EFFECT LESS THAN EXPECTED 3 0.0002
821 WHEEZING 12 0.0002
822 EPISTAXIS 15 0.0002
823 ADVERSE DRUG REACTION 18 0.0002
824 AGGRESSION 10 0.0002
825 BLOOD POTASSIUM DECREASED 6 0.0002
826 HEART RATE DECREASED 7 0.0002
827 HYPOAESTHESIA ORAL 3 0.0002
828 GASTROOESOPHAGEAL REFLUX DISEASE 16 0.0002
829 PRODUCT PHYSICAL ISSUE 4 0.0002
830 HYPERTENSION 42 0.0002
831 THERAPY INTERRUPTED 14 0.0002
832 CEREBRAL HAEMORRHAGE 7 0.0002
833 HYPONATRAEMIA 11 0.0002
834 DEVICE RELATED INFECTION 3 0.0002
835 PRODUCT PREPARATION ERROR 4 0.0002
836 LIMB DISCOMFORT 6 0.0002
837 DEPRESSION 44 0.0002
838 DELUSION 3 0.0002
839 BLOOD CHOLESTEROL INCREASED 9 0.0002
840 HAEMATOMA 5 0.0002
841 TOOTH LOSS 4 0.0002
842 BONE DENSITY DECREASED 6 0.0002
843 SEDATION 5 0.0002
844 CYANOSIS 3 0.0002
845 INJECTION SITE MASS 7 0.0002
846 NASAL CONGESTION 11 0.0002
847 MOVEMENT DISORDER 6 0.0002
848 IRRITABLE BOWEL SYNDROME 4 0.0002
849 FEAR 5 0.0002
850 CHEST DISCOMFORT 19 0.0002
851 BACK DISORDER 3 0.0002
852 ACCIDENTAL EXPOSURE TO PRODUCT 19 0.0002
853 CONSTIPATION 40 0.0002
854 TREATMENT NONCOMPLIANCE 10 0.0002
855 ANXIETY 52 0.0002
856 SUICIDE ATTEMPT 11 0.0002
857 ILL-DEFINED DISORDER 11 0.0002
858 MOBILITY DECREASED 13 0.0002
859 GAMMA-GLUTAMYLTRANSFERASE INCREASED 4 0.0002
860 VIRAL INFECTION 6 0.0002
861 BLOOD UREA INCREASED 3 0.0002
862 WOUND 5 0.0002
863 NEUROPATHY PERIPHERAL 17 0.0002
864 SNEEZING 4 0.0002
865 TYPE 2 DIABETES MELLITUS 6 0.0002
866 TRANSIENT ISCHAEMIC ATTACK 6 0.0002
867 HEMIPARESIS 3 0.0002
868 HEART RATE IRREGULAR 4 0.0002
869 INTERNATIONAL NORMALISED RATIO INCREASED 5 0.0002
870 DYSGEUSIA 13 0.0002
871 GASTRIC DISORDER 6 0.0002
872 SUICIDAL IDEATION 16 0.0002
873 ABORTION SPONTANEOUS 7 0.0002
874 ATRIAL FIBRILLATION 17 0.0002
875 PRODUCT SUBSTITUTION ISSUE 10 0.0002
876 HYPOKALAEMIA 8 0.0002
877 PERICARDIAL EFFUSION 4 0.0002
878 DYSPEPSIA 17 0.0002
879 PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME 4 0.0002
880 SWELLING 16 0.0002
881 PANCREATITIS 9 0.0002
882 COLD SWEAT 3 0.0002
883 BLOOD TRIGLYCERIDES INCREASED 3 0.0002
884 DISEASE PROGRESSION 20 0.0002
885 RENAL INJURY 5 0.0002
886 ISCHAEMIC STROKE 3 0.0002
887 CATARACT 10 0.0002
888 RHABDOMYOLYSIS 7 0.0002
889 GOUT 3 0.0002
890 FEELING ABNORMAL 40 0.0002
891 DIABETIC KETOACIDOSIS 4 0.0002
892 CONTUSION 16 0.0002
893 FEBRILE NEUTROPENIA 11 0.0002
894 OSTEOARTHRITIS 7 0.0002
895 MENTAL IMPAIRMENT 4 0.0002
896 FIBROMYALGIA 4 0.0002
897 NEURALGIA 4 0.0002
898 PLEURAL EFFUSION 10 0.0002
899 INJECTION SITE URTICARIA 4 0.0002
900 OSTEONECROSIS OF JAW 4 0.0002
901 ABDOMINAL DISCOMFORT 27 0.0002
902 MEMORY IMPAIRMENT 22 0.0002
903 LEUKOPENIA 8 0.0002
904 FOETAL EXPOSURE DURING PREGNANCY 13 0.0002
905 PAIN IN EXTREMITY 47 0.0002
906 HEAD INJURY 5 0.0002
907 PULMONARY EMBOLISM 15 0.0002
908 DIABETES MELLITUS 12 0.0002
909 JOINT SWELLING 19 0.0002
910 HYPOTHYROIDISM 5 0.0002
911 HAEMOGLOBIN DECREASED 16 0.0002
912 MALAISE 68 0.0002
913 EAR PAIN 3 0.0002
914 HAEMORRHOIDS 3 0.0002
915 PLASMA CELL MYELOMA 6 0.0002
916 ACTIVITIES OF DAILY LIVING IMPAIRED 3 0.0002
917 FULL BLOOD COUNT DECREASED 3 0.0001
918 BRONCHITIS 11 0.0001
919 DRUG EFFECT DECREASED 8 0.0001
920 STOMATITIS 9 0.0001
921 MIGRAINE 14 0.0001
922 INFLUENZA LIKE ILLNESS 12 0.0001
923 ABNORMAL DREAMS 4 0.0001
924 INTERSTITIAL LUNG DISEASE 7 0.0001
925 FALL 48 0.0001
926 DEMENTIA 4 0.0001
927 KNEE ARTHROPLASTY 3 0.0001
928 HYPERHIDROSIS 18 0.0001
929 DEEP VEIN THROMBOSIS 9 0.0001
930 DRUG EFFECT INCOMPLETE 5 0.0001
931 MALIGNANT NEOPLASM PROGRESSION 14 0.0001
932 THERAPY CESSATION 7 0.0001
933 ACUTE MYOCARDIAL INFARCTION 4 0.0001
934 NASOPHARYNGITIS 25 0.0001
935 PSYCHOTIC DISORDER 4 0.0001
936 GLOSSODYNIA 3 0.0001
937 PULMONARY OEDEMA 6 0.0001
938 THERAPEUTIC PRODUCT EFFECT DECREASED 6 0.0001
939 UNEVALUABLE EVENT 10 0.0001
940 INCORRECT DOSE ADMINISTERED 30 0.0001
941 EPILEPSY 4 0.0001
942 RENAL DISORDER 6 0.0001
943 THROMBOSIS 10 0.0001
944 INJECTION SITE PAIN 38 0.0001
945 LIVER INJURY 3 0.0001
946 DEATH 105 0.0001
947 EXTRAPYRAMIDAL DISORDER 3 0.0001
948 INFUSION RELATED REACTION 8 0.0001
949 WEIGHT INCREASED 27 0.0001
950 AGEUSIA 3 0.0001
951 POLLAKIURIA 5 0.0001
952 NEOPLASM MALIGNANT 8 0.0001
953 ROAD TRAFFIC ACCIDENT 5 0.0001
954 ANGER 4 0.0001
955 CARDIOVASCULAR DISORDER 3 0.0001
956 EXPOSURE VIA SKIN CONTACT 3 0.0001
957 INJECTION SITE BRUISING 9 0.0001
958 DISTURBANCE IN ATTENTION 6 0.0001
959 WRONG TECHNIQUE IN DRUG USAGE PROCESS 4 0.0001
960 RESTLESSNESS 4 0.0001
961 DYSURIA 4 0.0001
962 COGNITIVE DISORDER 5 0.0001
963 CARDIAC DISORDER 10 0.0001
964 INJECTION SITE ERYTHEMA 13 0.0001
965 CONTRAINDICATED PRODUCT ADMINISTERED 3 0.0001
966 CORONARY ARTERY DISEASE 3 0.0001
967 DYSKINESIA 4 0.0001
968 NEUTROPHIL COUNT DECREASED 4 0.0001
969 HAEMORRHAGE 10 0.0001
970 RECTAL HAEMORRHAGE 4 0.0001
971 HYPOACUSIS 4 0.0001
972 PRODUCT DOSE OMISSION 6 0.0001
973 INJECTION SITE PRURITUS 6 0.0001
974 RHEUMATOID ARTHRITIS 10 0.0001
975 LOWER RESPIRATORY TRACT INFECTION 4 0.0001
976 NEOPLASM PROGRESSION 3 0.0001
977 INJURY 6 0.0001
978 MULTIPLE SCLEROSIS 4 0.0001
979 CEREBROVASCULAR ACCIDENT 14 0.0001
980 NERVOUSNESS 4 0.0001
981 BLOOD GLUCOSE INCREASED 14 0.0001
982 ARTHROPATHY 4 0.0001
983 MEDICATION ERROR 4 0.0001
984 MYOCARDIAL INFARCTION 12 0.0001
985 HOSPITALISATION 10 0.0001
986 DRUG DOSE OMISSION 10 0.0001
987 DRUG ABUSE 5 0.0001
988 CHRONIC OBSTRUCTIVE PULMONARY DISEASE 3 0.0001
989 INJECTION SITE SWELLING 4 0.0001
990 CARDIAC FAILURE CONGESTIVE 4 0.0000
991 MULTIPLE SCLEROSIS RELAPSE 3 0.0000
992 BREAST CANCER 3 0.0000
993 DRUG DEPENDENCE 3 0.0000